A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine

Migraine Clinical Trial

Official title:

A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02378844
• Other study ID #: GM-11
• Status: Completed
• Phase: N/A
• Start date: June 2015
• Est. completion date: August 29, 2018

Study information

• Verified date: July 2019
• Source: ElectroCore INC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, double-blind, randomized, sham-controlled, multicentre investigation.

Description:

The study period will begin with a four week run-in period, during which there is no investigational treatment. The purpose of the run-in period will be observation for baseline comparison.

The run-in period will be, followed by a 12 week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment.

The randomized period will be followed by a 24 week open label period, where the subjects in the sham treatment group will switch in treatment assignment and receive a gammaCore®-R and the gammaCore®-R will continue to receive an active treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 477
• Est. completion date: August 29, 2018
• Est. primary completion date: February 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Is between the ages of 18 and 75 years.

2. Has been previously diagnosed with migraine (with or without aura) in accordance with the International Classification of Headache Disorders (ICHD)-3 Beta Classification criteria.

3. Experience between 5 and 12 migraine days per month (over the last 4 months) with at least 2 of the migraines lasting more than 4 hours.

4. Has age of onset of migraine less than 50 years old.

5. Agrees not to use any migraine prevention treatments (including Botox injections) and/or medications (exclusive of medications taken for acute relief of migraine symptoms).

6. Agrees to refrain from initiating or changing the type, dosage or frequency of any prophylactic medications for indications other than migraine that in the opinion of the clinician may interfere with the study objectives (e.g. antidepressant, anti convulsant, beta blockers, etc.).

7. Agrees to use the gammaCore®-R device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires.

8. Is able to provide written Informed Consent.

Exclusion Criteria:

1. Has a concomitant medical condition that will require oral or injectable steroids during the study.

2. Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma.

3. Has a structural abnormality at the gammaCore®-R treatment site (e.g lymphadenopathy previous surgery or abnormal anatomy).

4. Has pain at the gammaCore®-R treatment site (e.g.dysesthesia, neuralgia and/or cervicalgia).

5. Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or facial disorder) that in the opinion of the investigator may confound the study assessments

6. Has know or suspected severe cardiac disease(e.g. symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF)).

7. Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery).

8. Has an abnormal baseline Electrocardiogram (ECG) e.g. second and third degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction).

9. Has had a cervical vagotomy.

10. Has uncontrolled high blood pressure (systolic >160 diastolic > 100 after 3 repeated measurements within 24 hours).

11. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).

12. Has been implanted with metal cervical spine hardware or has a metallic implant near the gammaCore®-R stimulation site.

13. Has a known history of suspicion of secondary headache.

14. Has a history of syncope (within the last five years).

15. Has a history of seizures (within the last five years).

16. Has a known or suspicion of substance abuse or addiction (within the last 5 years).

17. Is using marijuana (including medical marijuana) for any indications, more than twice a month.

18. Currently takes simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) greater than 15 days per month or triptans, ergots or combined analgesics greater than 10 days per month for headaches or other body pain.

19. Currently takes prescription opioids greater than 2 days per month for headaches or body pain.

20. Has taken medications for migraine prophylaxis in the previous 30 days.

21. Has previous diagnosis of medication overuse headache (MoH) , which has reverted to episodic migraine within the last 6 months.

22. Meets the ICHD-3 Beta Classification criteria for chronic migraine (> 15 headache days per month).

23. Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine .

24. Has had surgery for migraine prevention.

25. Has undergone nerve block (occipital or other) in the head or neck within the last 2 months.

26. Has received Botox injections within the last 6 months.

27. Is pregnant or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use and accepted form of birth control.

28. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.

29. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).

30. Is a relative of or an employee of the investigator or the clinical study site.

31. Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the clinician may interfere with the study.

32. Has previously used the gammaCore® device.

Related Conditions & MeSH terms

• Migraine
• Migraine Disorders

Intervention

Device:
• gammaCore®-R
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
• gammaCore®-R Sham
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).

Locations

Country	Name	City	State
Belgium	Neurology Department, University of Liège	Liège
Denmark	Danish Headache Center	Glostrup
Germany	Neurologische Klinik und Poliklinik, Charité Campus Mitte	Berlin
Germany	Klinik für Neurologie, Universitätsklinikum Essen	Essen
Germany	CTC, University Medical Center Hamburg-Eppendorf	Hamburg
Germany	Migräne- und Kopfschmertzklinik Königstein	Königstein
Germany	Klinik für Neurologie, Ludwig-Maximilliams-Universität, Klinikum Grosshadern	München
Germany	Zentrum für Neurologie und Epileptologie, Hertie-Institut für Klinische Hirnforschung	Tübingen
Germany	DKD HELIOS Klinik Wiesbaden	Wiesbaden
Greece	Neurology Department, Athens Naval Hospital	Athens
Netherlands	Neurology Department, Leiden University Center	Leiden
Norway	Sandvika Nevrosenter AS	Sandvika
Spain	Headache Unit, University Hospital Vall d'Hebron	Barcelona
Spain	Servicio de Neurologia, Hospital Ruber Internacional	Madrid
Spain	Servicio de Neurologia, Clinica Universidad de Navarra	Pamplona
Spain	Servicio de Neurologia, Hospital Clinico Universitario de Valencia	Valencia
United Kingdom	Basildon University Hospital	Basildon	Essex
United Kingdom	School of Clinical and Expermental Medicine	Birmingham
United Kingdom	Neurology Department, The Southern Hospital	Glasgow
United Kingdom	Neurology Department, Hull Royal Infirmary	Hull
United Kingdom	Neurology Department, The Walton Center	Liverpool
United Kingdom	Neurology Department, King's College London	London

Sponsors (1)

Lead Sponsor	Collaborator
ElectroCore INC

Countries where clinical trial is conducted

Belgium,  Denmark,  Germany,  Greece,  Netherlands,  Norway,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Number of Migraine Days	Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.	last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.
Secondary	Number of Participants With 50% Responder Rate	The number of subjects with a reduction of 50% or more in number of migraine days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.	The last four weeks in the randomization period compared to the four week run-in period.
Secondary	Mean Change in Number of Headache Days	The mean change in number of headache days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period.	The last four weeks in the randomization period compared to the four week run-in period.
Secondary	Change in Number of Acute Medication Days	The mean change in number of acute medication days (as reported in the subject diary) from the run-in period to the last 4 weeks of the double-blind period	The last four weeks in the randomization period compared to the four week run-in period.
Secondary	Change in Headache Disability Using Headache Impact Test-6	Change in headache disability from the 4 week run-in period to the last 4 weeks of the randomized period as measured using the Headache Impact Test-6 (HIT-6). The HIT-6 measures the impact if a subject's headaches on their ability to function at work, at home and in social situations. Subjects are presented with 6 questions about ability to function and normal daily life and for each question they rate the impact of their headaches as 'never' (6 points) or 'rarely' (9 points) or 'sometimes' (10 points) or 'very often' (11 points) or 'always' (13 points). Minimum score = 36, maximum score = 78. A higher score indicates more impact.	From four week run-in period to last four weeks in the randomization period
Secondary	Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period	Migraine Disability Assessment (MIDAS) score from the end of run-in period to the end of randomized period. The MIDAS assessment measures the effect of headaches on a subject's daily functioning. It takes into account the past 3 months and is comprised of five questions. A lower score indicated less disability, a higher score indicates more disability. The scores are graded: 0-5, MIDAS Grade I, little disability 6-10, MIDAS Grade II, mild disability 11 to 20 MIDAS Grade III, moderate disability 21+ MIDAS Grade IV, severe disability	3 months - end of run-in period to end of randomized period
Secondary	Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)	The descriptive system comprises five dimensions (5D): mobility, self-care, usual activities, pain/discomfort and anxiety/depression.; Each dimension has 5 levels (5L): no problems (1) , slight problems (2), moderate problems (3), severe problems (4) and extreme problems (5).; Minimum score is 5 (no problems) and maximum score is 25 (extreme problems); An overall health question is asked using a visual analogue scale(VAS) from 0-100 where 0 is bad health and 100 good health	From four week run-in period to last four weeks in the randomization period
Secondary	Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)	Change in number of migraine days (as reported in subject diary) during the 6 month open label period compared to the baseline run-in period.	The 6 month open-label period compared to the four week run-in period
Secondary	Number of Participants With Adverse Events	Adverse Effects were collected for all subjects for the duration of the study.	up to Week 36
Secondary	Change in Headache Days in the Open Label Period	The mean change in number of headache days (as reported in the subject diary) during the open label period compared to the base-line run-in period	The 6 month open-label period compared to the four week run-in period